Keywords: Boehringer Ingelheim, Eli Lilly, Trajenta, IQWiG, AMNOG, Germany, Type 2 diabetes

Added benefit of Trajenta not proven, says German agency

Article | 10 January 2012

Print This

In an early benefit assessment under Germany’s "Act on the Reform of the Market for Medicinal Products” ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in